We take a look at the key microbiome therapeutics currently in the clinical pipeline for recurrent C. difficile infections and their prospects for the treatment of this disease in the future.
Browsing: Bacterial > Clostridium Difficile Infection
In our latest infographic we provide a visual snapshot of the infections and immune processes that have been linked with the microbiome thus far, explaining some of the evidence
As part of our focus around World Antibiotic Awareness Week (13–19 November) we spoke to Professor Jonathan Cooke, a pharmacologist and pharmacist based in the UK who holds a special interest in antimicrobial resistance. He shares his thoughts on this pressing issue below:
In this infographic we summarize the clinical candidates reported by the WHO – indicating which diseases they are active (or possibly active) against, whether they’re considered innovative and which Phase the trials are currently in.
An analysis of a large, nationwide health insurance database reveals a rapid increase in multiple recurring Clostridium difficile infections in the United States.
In research presented at ECCMID 2017, scientists have suggested foods should be investigated as potential source of C. difficile.
This study delves aims to evaluate the efficacy of durancin 61A as an inhibitor of resistant clinical pathogens and to shed light on its mode of action.
A study including over 10,000 patients has demonstrated a lower risk of all-cause 30-day mortality when Clostridium difficile infections are treated with vancomycin as opposed to metronidazole.
This perspective discusses the urgent need for novel and efficient antimicrobial strategies against C. difficile and the authors evaluate the application of the acyldepsipeptides family of antibiotics to treat C. difficile infections.